Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in Asia
Journal
Immunotherapy
Journal Volume
15
Journal Issue
13
Date Issued
2023-09
Author(s)
Cheng, Ying
Okamoto, Isamu
Zhang, Li
Hu, Jie
Wang, Donglin
Hu, Chengping
Zhou, Jianying
Wu, Lin
Cao, Lejie
Liu, Jiwei
Zhang, Helong
Sun, Hong
Wang, Ziping
Gao, Hongjun
Yan, Yan
Xiao, Suijun
Lin, Jianxin
Pietanza, M Catherine
Kurata, Takayasu
Abstract
Aim: We pooled patient-level data from three randomized controlled studies to evaluate the combination of pembrolizumab plus chemotherapy in patients with untreated advanced/metastatic non-small-cell lung cancer (NSCLC) and programmed cell death ligand 1 (PD-L1) tumor proportion score <1% in East Asia. Methods: The analysis included 107 patients from China, Japan, Korea, Thailand and Taiwan (pembrolizumab plus chemotherapy, n = 56; chemotherapy alone, n = 51). Results: For pembrolizumab plus chemotherapy versus chemotherapy alone, median overall survival was 21.3 versus 12.6 months (HR, 0.55 [95% CI: 0.35-0.87]) and median progression-free survival was 8.4 versus 6.0 months (HR, 0.64 [95% CI: 0.43-0.96]). Conclusion: The analysis supports the use of pembrolizumab in combination with platinum-based chemotherapy for East Asian patients with PD-L1-negative, advanced NSCLC.
Subjects
cancer immunology; checkpoint inhibitors; immunotherapy
SDGs
Type
journal article